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Abstract
Background: Young-onset breast cancer (<40 years) is associated with worse prognosis and higher mortality.
Breast cancer risk factors may contribute to distinct tumor biology and distinct age at onset, but understanding of
these relationships has been hampered by limited representation of young women in epidemiologic studies and
may be confounded by menopausal status.
Methods: We examined tumor characteristics and epidemiologic risk factors associated with premenopausal
women’s and young women’s breast cancer in phases I–III of the Carolina Breast Cancer Study (5309 cases, 2022
control subjects). Unconditional logistic regression was used to assess heterogeneity by age (<40 vs. ≥40 years) and
menopausal status.
Results: In both premenopausal and postmenopausal strata, younger women had more aggressive disease, including
higher stage, hormone receptor-negative, disease as well as increased frequency of basal-like subtypes, lymph node
positivity, and larger tumors. Higher waist-to-hip ratio was associated with reduced breast cancer risk among young
women but with elevated risk among older women. Parity was associated with increased risk among young women
and reduced risk among older women, while breastfeeding was more strongly protective for young women. Longer
time since last birth was protective for older women but not for young women. In comparison, when we stratified
by age, menopausal status was not associated with distinct risk factor or tumor characteristic profiles, except for
progesterone receptor status, which was more commonly positive among premenopausal women.
Conclusions: Age is a key predictor of breast cancer biologic and etiologic heterogeneity and may be a stronger
determinant of heterogeneity than menopausal status. Young women’s breast cancer appears to be etiologically and
biologically distinct from that among older women.
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Background
Breast cancer among young women (<40 years of age) is
associated with more proliferative disease, worse prog-
nosis, and higher mortality than disease among older
women (≥40 years) [1–6]. Young women have larger tu-
mors, higher-grade disease, hormone receptor negativity,
and lymph node positivity, which may contribute to
poorer disease outcomes [4–10]. Differences in the dis-
tribution of breast cancer risk factors (particularly race,
body size, and reproductive exposures) among younger
vs. older women may also contribute to differences in
tumor characteristics by age [7, 11–14]. However, find-
ings regarding associations between breast cancer risk
factors and age at diagnosis have been inconsistent.
Resolution of previous inconsistencies has been impeded
by limited representation of young women in most stud-
ies [7, 13–15], as less than 7 % of all breast cancers in
the United States are diagnosed among women <40 years
of age [5, 16] and by differences in defining “young”
women, with some studies equating young age with pre-
menopausal status and others using a variety of “young”
age cutoffs [13–15, 17–20]. While age and menopausal
status are strongly associated, these variables may have
independent effects on cancer development [6].
The present study was conducted within the Carolina
Breast Cancer Study (CBCS), a large, population-based
case-control study of breast cancer biology and epidemi-
ology enriched for breast cancers occurring among
young women. In our analysis, we had two objectives:
(1) to identify breast tumor characteristics and epidemi-
ologic risk factors associated with young vs. older
women’s breast cancer in the CBCS and (2) to assess
heterogeneity in these associations independently by age
(<40 years vs. ≥40 years) and menopausal status (pre- vs.
postmenopausal).
Methods
Study population
The CBCS is a population-based case-control study con-
ducted in 24 (phases I and II) and 44 (phase III) counties
of central and eastern North Carolina. Women were eli-
gible for inclusion if they were 20–74 years of age at the
time of diagnosis (cases) or study recruitment (control
subjects). As described previously [17, 21–23], the CBCS
researchers collected extensive clinical, molecular, and
epidemiologic data for in situ (phase II) and invasive
(phases I–III) breast cancer cases diagnosed from 1993
to 1996 (phase I), 1996 to 2001 (phase II), and 2008 to
2013 (phase III). Cases were identified through rapid
case ascertainment by the North Carolina Central Can-
cer Registry; control subjects were recruited (for phases
I and II only) through North Carolina Department of
Motor Vehicles records and Health Care Financing Ad-
ministration records for Medicare enrollment. Phase III
was conducted in 44 counties and recruited only patients
with invasive breast cancer. In all phases, randomized re-
cruitment was used to oversample younger (<50 years)
and African American cases as well as to frequency-match
control subjects to cases by age (<50 years vs. ≥50 years),
5-year age group, and self-reported race (African American
vs. non-African American) [21]. The response rates for
cases and control subjects in phases I and II have been re-
ported previously [24]. For phase III cases, the overall con-
tact rate (contacted/eligible) was 95.5 %, the cooperation
rate (enrolled/contacted) was 75.8 %, and the overall re-
sponse rate (product of contact and cooperation rates) was
72.0 %. The present analysis included all cases (n = 5309)
from phases I–III for case-case analyses as well as phases I
and II cases (n = 2311) and control subjects (n = 2022) for
case-control analyses. All study protocols were approved
by the University of North Carolina (UNC) School of
Medicine Institutional Review Board, and all participants
gave their written informed consent.
Data collection
Breast tumor tissue and medical records were obtained
from local hospitals for all in situ and invasive breast
cancer cases. Stage at diagnosis (in situ, stages I–IV),
lymph node status (positive vs. negative for metastasis),
estimated tumor size (>2 cm, ≤2 cm), nuclear grade
(marked, slight/moderate pleomorphism), and histologic
grade (poorly, moderately/well-differentiated) were ob-
tained from medical record reviews, although nuclear
and histologic grade data were unavailable for all phase
II cases. Immunohistochemistry (IHC) assays conducted
at the UNC Immunohistochemistry Core Laboratory
were completed to define human epidermal growth fac-
tor receptor 2 (HER2) status (positive defined as ≥10 %
cells staining vs. negative) [24]. Estrogen receptor (ER)
and progesterone receptor (PR) status information was
obtained from medical records when available (88 %) or
by IHC at UNC (12 %), with ER/PR positivity defined as
≥5–10 % cells with nuclear staining [25]. A 10 % random
sample of cases showed high agreement between ER sta-
tus obtained from medical records and IHC assays at
UNC (k-statistic = 0.62, concordance = 81 %) [25]. Breast
cancer subtype was defined on the basis of ER, PR,
HER1, HER2, and cytokeratin (CK) 5/6 positivity as pre-
viously described [25]: basal-like (ER−, PR−, HER2−,
HER1+, and/or CK 5/6+), luminal (ER+ and/or PR+),
HER2+/ER− (ER−, PR−, HER2+), and unclassified (nega-
tive for all five markers). Collection of molecular subtype
data is ongoing for phase III cases; only phases I and II
cases were included in analyses of these characteristics.
In-home interviews were conducted by study nurses
for all cases and control subjects [17]. Participants were
asked questions regarding their reproductive and med-
ical histories as well as exogenous hormone exposures.
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Nurses also measured body weight, height, waist circum-
ference, and hip circumference during the interview. All
breast cancer risk factors were categorized as previously
reported [17]. Briefly, menopausal status was defined as
pre- or postmenopausal on the basis of self-reported ces-
sation of menstruation for women over age 50 years;
women under age 50 years were defined as premeno-
pausal unless they had reported undergoing menopause-
related cessation of menstruation, bilateral oophorectomy,
or ovarian irradiation. Body mass index (BMI) was defined
as body weight/height ratio in kilograms per square meter
using categories of the National Heart, Lung, and Blood
Institute (normal/underweight <25 kg/m2, overweight
25.0–29.9 kg/m2, and obese ≥30 kg/m2) [26]. Waist-to-hip
ratio (WHR) was calculated as the waist/hip circumfer-
ence ratio in centimeters and categorized as <0.77 cm,
0.77–0.83 cm, and ≥0.84 cm. Classifications for other risk
factors were consistent with previous CBCS analyses [17]:
age at menarche (<13 years, ≥13 years), parity (nullipar-
ous, 1–2 births, ≥3 births), age at first live birth (<26 years,
≥26 years), history of breastfeeding (never, ever), lifetime
duration of breastfeeding (never, >0–3 months, ≥4 months),
and oral contraceptive use (never, ever).
Statistical analysis
To examine the baseline exposure distributions, descrip-
tive analyses examining the distribution of breast cancer
risk factors among all control subjects were conducted.
For case-case analyses of tumor characteristics, uncondi-
tional logistic regression was used to calculate ORs and
95 % CIs. Age and menopausal status are strongly corre-
lated but may influence breast cancer etiology through
distinct mechanisms. To estimate age effects independ-
ent of menopausal status, case-case analyses were re-
stricted to premenopausal cases (n = 2373). Similarly, to
consider the effects of menopause independent of age,
case-case analyses were conducted among women
≥40 years of age. However, postmenopausal women
≥40 years of age represent a wide range of ages (40–74
years), and associations estimated within this group are
susceptible to residual confounding by age. Therefore,
we conducted a sensitivity analysis estimating case-case
associations for tumor characteristics among pre- vs.
postmenopausal women aged 40–49 years and 40–59
years of age. Analyses were conducted among all women
and stratified by race (African American and non-
African American) to examine effect measure modifica-
tion by race.
Case-control analyses were conducted for breast can-
cer risk factors, stratifying by age at diagnosis or meno-
pausal status. Unconditional logistic regression, with an
offset term to account for the sampling probabilities of
cases and control subjects, was used to estimate case-
control ORs and 95 % CIs for each risk factor. Young
(<40 years) vs. older (≥40 years) groups were evaluated
among premenopausal women and pre- vs. postmeno-
pausal status was evaluated among women ≥40 years.
All analyses were adjusted for age (5-year age categories)
and race (African American vs. non-African American).
Similar to the case-case analyses described above, we re-
stricted our analyses of risk factor associations by meno-
pausal status to pre- and postmenopausal women aged
40–59 years to address residual confounding by age and
to control for nonpositivity (i.e., the lack of premeno-
pausal women above age 59 years). Heterogeneity in risk
factor associations by age or menopausal status was eval-
uated by conducting likelihood ratio tests in which the
estimated log-likelihood of adjusted models was com-
pared with that of the adjusted model including a multi-
plicative interaction term for age (or menopausal status)
and the corresponding risk factor. Statistically significant
heterogeneity was defined with α = 0.1. To explore racial
differences in etiologic heterogeneity by age and meno-
pausal status, case-control analyses were further strati-
fied by race. Models for age at first live birth, history of
breastfeeding, and lifetime breastfeeding duration were
restricted to parous women. Statistical significance was
defined with α = 0.05. All analyses were performed using
SAS version 9.3 software (SAS Institute, Cary, NC, USA).
Results
To identify possible confounders of the risk factor and
age-at-diagnosis association, we examined the distribution
of breast cancer risk factors among young (<40 years) vs.
older (≥40 years) control subjects (Table 1). Although the
majority of control subjects were white (59.3 % vs. 40.7 %
for African American and other race combined), young
control subjects were more likely to be African American
or of another race. Young control subjects had lower BMI
and WHR, earlier menarche, lower parity, older age at first
birth, greater history of ever breastfeeding, longer duration
of breastfeeding, and higher oral contraceptive use than
older control subjects. Risk factors that showed differential
distributions among control subjects, overall and by race
(Additional file 1: Table S1), were included in multivari-
able models.
Tumor characteristic and risk factor associations
according to age at diagnosis
Tumor characteristics for in situ and invasive cases were
examined together in this study, as sensitivity analyses
did not reveal any difference in results when excluding
in situ cases (results not shown) nor any difference in
the prevalence of in situ cases by age (Table 2). In logis-
tic regression analyses of the relationship between young
age at diagnosis and tumor characteristics, young women
had more aggressive tumors (Table 2); specifically, young
women’s tumors were more likely to be higher stage and
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basal-like breast cancers. Young women also had signifi-
cantly more ER and PR negative disease with a greater fre-
quency of marked pleomorphism, positive lymph nodes,
and larger tumor size. Although not significantly different,
HER2 positivity and more poorly differentiated histologic
grade were more common among young women.
To evaluate whether young- and older-onset breast
cancers are etiologically distinct, we estimated associa-
tions with risk factors stratified by age (Table 3). These
analyses were restricted to premenopausal women to
avoid confounding by menopausal status. Age appeared
to modify associations for several risk factors. Ever-
breastfeeding and a lifetime breastfeeding duration
≥4 months were associated with reduced risk of young-
onset (<40 years of age) breast cancer and no change in
risk of older-onset (≥40 years) disease. Likelihood ratio
tests showed significant effect measure modification by
age for both ever-breastfeeding (interaction p = 0.003)
and duration of breastfeeding (interaction p = 0.04). Par-
ity and longer time since last term pregnancy (10–19
years) were protective among older women and had ei-
ther null or weakly increased risk for young women,
although this heterogeneity was not statistically signifi-
cant. High WHR was protective among younger cases
and either null (BMI) or associated with elevated risk
(WHR) among older women. Oral contraceptive use was
more strongly, but not significantly, associated with risk
among younger women, while associations with BMI,
age at first birth, age at last birth, and age at menarche
were similar between young and older premenopausal
cases. Thus, patterns of risk factor associations differed
substantially between young and older premenopausal
women.
Tumor characteristic and risk factor associations by
menopausal status
Relative to the age patterns described above, associations
with menopausal status were attenuated. After restrict-
ing to cases ≥40 years of age, we assessed the association
between menopausal status and tumor characteristics. In
crude analyses, premenopausal status appeared to be as-
sociated with poor-prognosis tumor characteristics simi-
lar to those observed when we compared young and
older premenopausal women. Premenopausal cases were
Table 1 Characteristics of control subjects by age in Carolina
Breast Cancer Study phases I and II (n = 2022)
Risk factor <40 years, n (%) ≥40 years, n (%)
Mean age (±SD) 35.3 (±3.2) 54.8 (±9.9)
Race
White 120 (52.0) 1080 (60.3)
African American 104 (45.0) 684 (38.2)
Other 7 (3.0) 27 (1.5)
BMI
< 25 kg/m2 (normal/underweight) 97 (42.0) 652 (37.0)
25–29.9 kg/m2 (overweight) 60 (26.0) 541 (30.7)
≥ 30 kg/m2 (obese) 74 (32.0) 570 (32.3)
Missing 28
WHR
< 0.77 92 (41.1) 523 (29.6)
0.77–0.83 71 (31.7) 575 (32.5)
≥ 0.84 61 (27.2) 671 (37.9)
Missing 7 22
Parity
Nulliparous 50 (21.7) 180 (10.1)
1–2 births 138 (59.7) 875 (48.9)
≥ 3 births 43 (18.6) 736 (41.1)
History of breastfeedinga
Never 83 (45.9) 906 (56.4)
Ever 98 (54.1) 700 (43.6)
Lifetime breastfeeding durationa
Never 92 (50.8) 925 (57.7)
> 0–3 months 27 (14.9) 225 (14.0)
≥ 4 months 62 (34.3) 453 (28.3)
Missing 3
Time since last term pregnancya
< 10 years 124 (68.5) 82 (5.1)
10–19 years 53 (29.3) 397 (24.7)
≥ 20 years 4 (2.2) 1126 (70.2)
Age at first live birtha
< 26 years 111 (61.3) 1235 (76.9)
≥ 26 years 70 (38.7) 371 (23.1)
Age at last live birtha
< 30 years 109 (60.2) 976 (60.8)
≥ 30 years 72 (39.8) 629 (39.2)
Missing 1
Age at menarche
< 13 years 117 (50.9) 825 (46.2)
≥ 13 years 113 (49.1) 959 (53.8)
Missing 1 7
Table 1 Characteristics of control subjects by age in Carolina
Breast Cancer Study phases I and II (n = 2022) (Continued)
Oral contraceptive use
Never 34 (14.7) 694 (39.0)
Ever 197 (85.3) 1084 (61.0)
Missing 13
BMI body mass index, WHR waist-to-hip ratio
aAmong parous women
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significantly less likely to have in situ disease and ER
positivity and more likely than postmenopausal women
to have stage II, III, or IV disease; higher histologic and
nuclear grade; lymph node positivity; and greater tumor
size (Additional file 2: Table S2). However, after adjust-
ing for age and/or restricting the age range of women to
control for nonpositivity (i.e., the lack of premenopausal
women above age 59 years), we observed that few
changes persisted. Among women aged 40–49 years,
only PR status and nuclear grade showed differences by
menopausal status; premenopausal women had higher
PR positivity and less marked pleomorphism. Among
women aged 40–59 years, premenopausal women had a
greater likelihood of stage II and PR+ disease as well as
larger tumors than postmenopausal women (Additional
file 2: Table S2); however, strata for premenopausal
women over age 50 years were very sparse, leading to
some instability of estimates. These results suggest that,
while menopausal status may be associated with some
tumor characteristics, associations are weaker than those
by age.
Similarly, stratification on menopausal status showed
limited evidence of etiologic heterogeneity (Additional
file 3: Table S3). Only age at last birth showed significant
modification by menopausal status (p = 0.01), in that age
at last birth ≥30 years was not associated with increased
risk among premenopausal women but did increase risk
among postmenopausal women. No other risk factors
were differentially associated with pre- or postmeno-
pausal breast cancer after adjusting for age and race.
Racial differences in tumor characteristics and risk factor
associations by age and menopausal status
In race-stratified analyses, associations between young
age and tumor characteristics were more precise among
white women but were similar in direction (results not
shown). Only HER2 positivity, lymph node positivity,
and histologic grade showed a suggestion of heterogen-
eity by race: Young age was associated with increased
HER2 positivity (OR 1.72, 95 % CI 1.08–2.72) and in-
creased lymph node positivity (OR 1.35, 95 % CI 1.04–
Table 2 Case-case ORs of tumor characteristics by age among
premenopausal cases in Carolina Breast Cancer Study phases I–III
(n = 2373)
Age <40 years Age ≥40 years
(reference)
Tumor characteristic n (%) OR (95 % CI) n (%)
Mean age (±SD) 34.8 (±3.7) 45.4 (±3.5)
Stage
In situ 35 (5.4) 0.98 (0.65–1.49) 125 (7.5)
Stage I 163 (25.3) 1.0 573 (34.5)
Stage II 340 (52.7) 1.74 (1.40–2.16) 687 (41.4)
Stage III 84 (13.0) 1.34 (0.99–1.82) 220 (13.3)
Stage IV 23 (3.6) 1.47 (0.88–2.46) 55 (3.3)
Missing 19 51
Subtypea
Luminal 106 (52.0) 1.0 283 (65.2)
Basal-like 51 (25.0) 1.87 (1.22–2.84) 73 (16.8)
HER2 18 (8.8) 1.72 (0.91–3.23) 28 (6.5)
Unclassified 29 (14.2) 1.55 (0.93–2.58) 50 (11.5)
Missing 109 286
ER status
Negative 270 (44.9) 1.0 515 (33.4)
Positive 332 (55.1) 0.62 (0.51–0.75) 1028 (66.6)
Missingb 62 168
PR status
Negative 302 (53.6) 1.0 544 (37.6)
Positive 261 (46.4) 0.52 (0.43–0.63) 903 (62.4)
Missingb 101 264
HER2 statusa
Negative 194 (77.0) 1.0 447 (82.3)
Positive 58 (23.0) 1.39 (0.96–2.01) 96 (17.7)
Missing 61 177
Histologic gradec
Well-differentiated/
moderate differentiation
89 (21.3) 1.0 268 (25.6)
Poor differentiation 328 (78.7) 1.27 (0.97–1.66) 779 (74.4)
Missingb 82 238
Nuclear gradec
Slight/moderate
pleomorphism
174 (41.2) 1.0 557 (52.2)
Marked pleomorphism 248 (58.8) 1.55 (1.24–1.95) 511 (47.8)
Missingc 77 217
Node status
Negative 329 (53.4) 1.0 907 (58.4)
Positive 287 (46.6) 1.23 (1.02–1.48) 645 (41.6)
Missingb 48 159
Table 2 Case-case ORs of tumor characteristics by age among
premenopausal cases in Carolina Breast Cancer Study phases I–III
(n = 2373) (Continued)
Tumor size
≤ 2 cm 233 (38.4) 1.0 749 (48.8)
> 2 cm 373 (61.6) 1.53 (1.26–1.85) 786 (51.2)
Missingb 58 176
ER estrogen receptor, HER2 human epidermal growth factor receptor 2, PR
progesterone receptor
aExcludes phase III cases
bMissing data due to ongoing data collection for phase III cases
cExcludes phase II cases
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Table 3 Case-control ORs of breast cancer risk factors by age among premenopausal women in Carolina Breast Cancer Study
phases I and II (n = 1904)
Age <40 years Age ≥40 years Test for heterogeneity
Risk factor Control subjects,
n (%)
Cases, n (%) OR (95 % CI)a Control subjects,
n (%)
Cases, n (%) OR (95 % CI)a χ2 test, df (p value)b
BMI, kg/m2
< 25.0 93 (41.9) 154 (49.2) 1.0 255 (40.0) 316 (44.3) 1.0 0.13, 2 (0.9)
25–29.9 58 (26.1) 71 (22.7) 0.72 (0.45–1.13) 184 (28.9) 181 (25.4) 0.87 (0.65–1.14)
≥ 30.0 71 (32.0) 88 (28.1) 0.73 (0.47–1.13) 198 (31.1) 217 (30.4) 0.98 (0.74–1.29)
Missing 12 6
WHR
< 0.77 89 (41.4) 135 (44.3) 1.0 235 (36.8) 231 (32.4) 1.0 2.47, 2 (0.3)
0.77–0.83 68 (31.6) 98 (32.1) 0.94 (0.61–1.43) 209 (32.7) 245 (34.4) 1.42 (1.08–1.86)
≥ 0.84 58 (27.0) 72 (23.6) 0.86 (0.54–1.36) 195 (30.5) 237 (33.2) 1.58 (1.18–2.11)
Missing 7 8 10 7
Parity
Nulliparous 49 (22.1) 70 (22.4) 1.0 76 (11.7) 106 (14.7) 1.0 3.55, 2 (0.2)
1–2 births 133 (59.9) 180 (57.5) 1.05 (0.67–1.63) 383 (59.0) 420 (58.3) 0.82 (0.58–1.14)
≥ 3 births 40 (18.0) 63 (20.1) 1.29 (0.74–2.27) 190 (29.3) 194 (26.9) 0.81 (0.55–1.18)
History of breastfeedingc
Never 77 (44.5) 145 (60.2) 1.0 343 (60.2) 370 (60.6) 1.0 9.01, 1 (0.003)
Ever 96 (55.5) 96 (39.8) 0.48 (0.31–0.75) 227 (39.8) 241 (39.4) 0.90 (0.70–1.16)
Lifetime breastfeeding durationc
Never 86 (49.7) 148 (61.4) 1.0 346 (60.7) 378 (61.9) 1.0 6.36, 2 (0.04)
> 0–3 months 25 (14.5) 33 (13.7) 0.79 (0.43–1.45) 69 (12.1) 65 (10.6) 0.86 (0.58–1.25)
≥ 4 months 62 (35.8) 60 (24.9) 0.50 (0.30–0.81) 155 (27.2) 168 (27.5) 0.87 (0.65–1.15)
Time since last term pregnancyc
< 10 years 119 (68.8) 169 (70.1) 1.0 76 (13.3) 108 (17.7) 1.0 4.44, 2 (0.1)
10–19 years 50 (28.9) 66 (27.4) 1.02 (0.64–1.63) 302 (53.0) 283 (46.3) 0.71 (0.50–1.01)
≥ 20 years 4 (2.3) 6 (2.5) 1.14 (0.30–4.27) 192 (33.7) 220 (36.0) 0.96 (0.64–1.43)
Age at first live birthc
< 26 years 103 (59.5) 146 (60.6) 1.0 386 (67.7) 414 (67.8) 1.0 0.00, 1 (1.0)
≥ 26 years 70 (40.5) 95 (39.4) 1.03 (0.68–1.58) 184 (32.3) 197 (32.2) 0.93 (0.71–1.20)
Age at last live birthc
< 30 years 102 (59.0) 148 (61.4) 1.0 344 (60.4) 362 (59.2) 1.0 0.01, 1 (0.9)
≥ 30 years 71 (41.0) 93 (38.6) 1.01 (0.67–1.54) 226 (35.6) 249 (40.8) 0.99 (0.78–1.26)
Age at menarche
< 13 years 111 (50.2) 170 (54.3) 1.0 323 (49.8) 393 (54.6) 1.0 0.01, 1 (0.9)
≥ 13 years 110 (49.8) 143 (45.7) 0.85 (0.59–1.20) 326 (50.2) 327 (45.4) 0.83 (0.66–1.03)
Missing 1
Oral contraceptive use
Never 33 (14.9) 36 (11.5) 1.0 112 (17.3) 125 (17.4) 1.0 0.67, 1 (0.4)
Ever 189 (85.1) 276 (88.5) 1.32 (0.78–2.22) 534 (82.7) 593 (82.6) 0.93 (0.70–1.25)
Missing 1 3 2
BMI body mass index, WHR waist-to-hip ratio
aAdjusted for matching factors race and age
bLikelihood ratio tests were performed to assess age-related heterogeneity in risk factor associations by comparing the estimated log-likelihood of adjusted models with
that of the adjusted model including a multiplicative interaction term for age and the corresponding risk factor (e.g., BMI × age). Statistically significant heterogeneity by
age was defined with α = 0.1
cAmong parous women
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1.76) among premenopausal white women but not
African American women (HER2 OR 1.03, 95 % CI
0.56–1.92; lymph node OR 1.07, 95 % CI 0.82–1.40).
Additionally, among white women, younger cases had a
higher prevalence of poorly differentiated histologic
grade (OR 1.63, 95 % CI 1.13–2.36); this association was
qualitatively different among African American women
(OR 0.86, 95 % CI 0.57–1.30). No strong heterogeneity
by race was observed in the associations between tumor
characteristics and menopausal status after controlling
for age at diagnosis (results not shown).
Likewise, little heterogeneity was observed by race for
associations between breast cancer risk factors and
menopausal status. With regard to breast cancer risk
factors, higher WHR increased risk among African
American women regardless of age, while age appeared
to modify the association between WHR and risk in
white women (results not shown). History of breastfeed-
ing and longer breastfeeding duration strongly reduced
risk among both young and older African American
women (history of breastfeeding: young OR 0.50, 95 %
CI 0.25–1.00; older OR 0.59, 95 % CI 0.38–0.92; breast-
feeding duration: young OR 0.47, 95 % CI 0.20–1.11;
older OR 0.56, 95 % CI 0.32–0.98), while the protective
effect of breastfeeding in white women appeared to be
restricted to young women. No other risk factors were
associated with breast cancer risk in race- and age-
stratified analyses.
Discussion
Among premenopausal women in the CBCS, early-onset
breast cancers (<40 years) are more aggressive than
those among older women. Young women had more ad-
vanced stage disease at diagnosis, larger tumors, more
hormone receptor-negative disease, marked pleomorph-
ism, and lymph node positivity than older women. We
also found that younger cases were more likely to be
nonwhite and to have reduced adiposity (lower WHRs)
than older cases. We found evidence for the dual effects
of parity on risk, similar to other previous studies
[14, 27–29]; namely, breast cancer risk was associated
with higher parity among young women but not older
women. Additionally, greater time since last birth was sig-
nificantly protective for older women but not young
women. Both history of breastfeeding and increased
breastfeeding duration significantly reduced the risk of
breast cancer among young but not older women, under-
scoring the importance of breastfeeding in mitigating
parity-associated risk among young women [7, 17, 30, 31].
Together these results suggest a unique pattern of risk fac-
tors for young women’s breast cancer.
This heterogeneity in the prevalence of aggressive
tumor characteristics by age at diagnosis has been well-
documented [5–10, 32], and our work supports the
hypothesis that young women’s breast cancer may be
biologically and/or clinically distinct from disease in
older women. Patterns for PR were interesting, first
showing that younger women were significantly more
likely to have PR negative disease, a finding that is well-
established in the literature [5–7, 9]. This is in contrast
to our finding that, among older women, premenopausal
cases had increased PR positivity compared with post-
menopausal cases, even after accounting for differences
in age. Talley et al. [33] found a similar suggestion of in-
creased PR positivity in premenopausal (compared with
postmenopausal) women, although the association was
not statistically significant. The complex effects on PR
expression are difficult to interpret and may reflect a
combination of etiologic and progression events; young
women may be more likely to get receptor negative dis-
ease, but older women developing PR+ disease may lose
receptor expression as menopause ensues. Further work
examining PR positivity in relation to age and meno-
pausal status is warranted to replicate these findings.
Moreover, many of the associations we detected may re-
flect a complex combination of etiologic and progression
differences. Previous epidemiologic studies have identi-
fied heterogeneity in the associations between breast
cancer risk factors and risk of distinct tumor subtypes.
For example, reproductive and body size exposures are
differentially associated with luminal and basal-like tu-
mors [17, 34]. Breastfeeding reduces risk of ER− breast
cancer and in our study is associated with young
women’s breast cancer. It is possible that patterns of
tumor characteristics by age, both in our present study
and in other previous studies, reflect these underlying
etiologic assumptions.
Young age and premenopausal status have often been
used almost interchangeably to define women with
early-onset breast cancer; however, we observed that
these factors may be better considered as separate fac-
tors. While young vs. older age at onset produced pat-
terns similar to those of pre- vs. postmenopausal status,
nearly all menopause associations (with the exception of
PR status and nuclear grade) became null after restrict-
ing on age, suggesting that heterogeneity in breast can-
cer characteristics by menopausal status was driven by
differences in age. Previous studies have also suggested
age-confounding of menopause etiologic associations;
for example, Lee et al. [35] reported significant differ-
ences in the association between dietary exposures and
pre- vs. postmenopausal breast cancer that were then
found to be attributable to age differences across meno-
pausal status. Given the strong association between age
and menopausal status, examining the independent con-
tributions of these factors on breast cancer risk is chal-
lenging. In our study, adjusting for age or menopausal
status as confounders in regression models was hampered
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by nonpositivity, as few women <40 years old were post-
menopausal in the CBCS. We restricted age comparisons
to premenopausal women and menopausal comparisons
to older women, thereby estimating the relative contribu-
tions of age and menopausal status independently and
avoiding nonpositivity issues in our analyses. While ana-
lyses restricted on age or menopausal status may limit
generalizability (i.e., the results for pre- vs. postmeno-
pausal comparisons may not apply to women with very
early menopause before age 40), increased internal validity
helps to dissect the relative importance of age and meno-
pausal status in etiology.
We observed limited heterogeneity by race in our ana-
lyses, suggesting that young women’s breast cancers may
have similar etiologies and biological characteristics re-
gardless of race. However, African American women
have higher breast cancer incidence prior to age 40 years
[32, 36–38], making young women’s breast cancer par-
ticularly relevant. Considering tumor characteristics, it is
well-established that poor prognostic features are more
prevalent among young and African American women
[5, 8, 25], but other work in the CBCS and other study
populations has shown that age-associated tumor char-
acteristics are similar by race [6, 8]. Using a subset of
the included data presented here, Furberg et al. [8]
previously reported that young (<40 years) African
American and white women differed only by the preva-
lence of ER and PR positivity. Considering breast cancer
risk factors, only body size (WHR) and breastfeeding
were differentially associated with age at onset among
African American and white women. Other studies have
observed heterogeneity in breast cancer risk by age and
race according to parity, oral contraceptive use, and age
at menarche [39, 40], associations that we did not ob-
serve in our study.
Our results should be interpreted in light of some lim-
itations. Analyses of tumor subtype, HER2 status, and
histologic/nuclear grade were limited by missing data for
some tumors. Data for tumor grade were unavailable for
phase II cases, and data collection for HER2 status is
currently ongoing for phase III of the CBCS. In prior
work considering the association between HER2 and age
at diagnosis, researchers reported mixed findings, al-
though recent studies have suggested increased HER2
positivity among young women [4, 10, 32]. We observed
a higher prevalence, though not significantly, of HER2+
tumors among young women. Additionally, in our ana-
lyses of ER and PR positivity, we used 5–10 % nuclear
staining to define hormone receptor positivity, consist-
ent with clinical standards during the study period.
However, this cutpoint differs from current guidelines is-
sued by the American Society of Clinical Oncology/Col-
lege of American Pathologists, which recommend a 1 %
positivity cutpoint [41]. Recent findings suggest that a
10 % cutpoint was preferable for identifying intrinsic
subtypes [42], suggesting that the impact of clinical
thresholds on interpretation of epidemiologic findings
remains uncertain. Finally, screen-detected breast can-
cers tend to be less advanced than those that are self-
detected or clinically detected [43, 44], and young
women <40 years of age do not typically receive mam-
mographic screening. Screening differences may account
for some of the observed heterogeneity in tumor aggres-
siveness by age, but they would be unlikely to account
for differences in etiology.
Conclusions
Our findings suggest that young women’s breast cancer
is biologically and possibly etiologically distinct from
breast cancers arising in older women. Age appears to
be a key driver for breast cancer heterogeneity that is at
least as important, or perhaps even more important,
than the effects of menopausal status. Clarifying the
etiologic and biological features of young women’s breast
cancer is important for identifying modifiable targets for
prevention of aggressive, early-onset breast cancers.
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